Morning Lantus [insulin glargine] v. intermediate-acting insulin 2x/day as basal insulin in a muliple daily inj. w/ Humalog [insulin lispro] in adolescents w/ type 1 diabetes mellitus: an active-controlled, open, randomized, gender-stratified, two-arm, parallel-group study

Trial Profile

Morning Lantus [insulin glargine] v. intermediate-acting insulin 2x/day as basal insulin in a muliple daily inj. w/ Humalog [insulin lispro] in adolescents w/ type 1 diabetes mellitus: an active-controlled, open, randomized, gender-stratified, two-arm, parallel-group study

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2011

At a glance

  • Drugs Insulin glargine; Insulin suspension isophane; Insulin zinc suspension
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Aventis Pharmaceuticals; Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2009 Pharmacodynamic substudy published in Diabetes Care.
    • 05 Aug 2008 The expected completion date for this trial is now 1 Feb 2005.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top